IMAGING CORE: NAPS2 DaT Core

Overview

Información sobre este estudio

The objectives of this study are:

  • To conduct research on RBD as a prodromal manifestation of DLB, PD, and MSA to address several of the NAPA ADRD priorities for LBD research as well as similar priorities for PD and MSA.  Investigate RBD occurring in prodromal synucleinopathy.
  • To enroll RBD participants and matched control participants for longitudinal, standardized collection of clinical, PSG, genetic, biofluid, and neuroimaging data.
  • To analyze collected data against longitudinal clinical outcomes to refine scales and develop /analyze biomarkers to optimally design clinical trials.
  • To share data, samples, and methods for use by the scientific community.
  • To interact with NIH, other scientific groups on RBD and overt synucleinopathies, industry partners, patients, and other groups.
  • To prepare for large-scale clinical trials.

 

 

The Neuroimaging Core is responsible for imaging operations at 10 NAPS sites, Harmonization and maintenance of the DaTscan protocols, quality control and storage of the imaging data, analysis and sharing of the imaging data.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Val Lowe, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20545142

Mayo Clinic Footer